Induced pluripotent stem cells for therapy personalization in pediatric patients:Focus on drug-induced adverse events

Adverse drug reactions(ADRs)are major clinical problems,particularly in special populations such as pediatric patients.Indeed,ADRs may be caused by a plethora of different drugs leading,in some cases,to hospitalization,disability or even death.In addition,pediatric patients may respond differently to drugs with respect to adults and may be prone to developing different kinds of ADRs,leading,in some cases,to more severe consequences.To improve the comprehension,and thus the prevention,of ADRs,the set-up of sensitive and personalized assays is urgently needed.Important progress is represented by the possibility of setting up groundbreaking patient-specific assays.This goal has been powerfully achieved using induced pluripotent stem cells(iPSCs).Due to their genetic and physiological species-specific differences and their ability to be differentiated ideally into all tissues of the human body,this model may be accurate in predicting drug toxicity,especially when this toxicity is related to individual genetic differences.This review is an up-to-date summary of the employment of iPSCs as a model to study ADRs,with particular attention to drugs used in the pediatric field.We especially focused on the intestinal,hepatic,pancreatic,renal,cardiac,and neuronal levels,also discussing progress in organoids creation.The latter are three-dimensional in vitro culture systems derived from pluripotent or adult stem cells simulating the architecture and functionality of native organs such as the intestine,liver,pancreas,kidney,heart,and brain.Based on the existing knowledge,these models are powerful and promising tools in multiple clinical applications including toxicity screening,disease modeling,personalized and regenerative medicine.

Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents

Objective:To assess the hepatoprotective effect of Solanum xanthocarpum(S. xanthocarpum) fruit extract against antitubercular drug-induced liver toxicity in experimental animals.Methods:Ethanolic(50%) fruit extract ofS. xanthocarpum(100, 200 and 400 mg/kg bw) was administered daily for 35 days in experimental animals. Liver toxicity was induced by combination of three antitubercular drugs [isoniazid(I) 7.5 mg/kg, rifampicin(R) 10 mg/kg and pyrazinamide(P) 35 mg/kg] given orally as suspension for 35 days in rats. The hepatoprotective activity was assessed using various biochemical parameters like aspartate aminotransferase(AST), alanine aminotransferase(ALT), alkaline phosphatise(ALP), total bilirubin(TBL), albumin(ALB), total protein(TP), lactate dehydroginase(LDH), and serum cholesterol(CHL). Meanwhile,in vivoantioxidant activities as lipid peroxidation(LPO), reduced glutathione(GSH), superoxide dismutase(SOD) and catalase(CAT) were measured in rat liver homogenate. The biochemical observations were supplemented by histopathological examination.Results:The results demonstrated that treatment withS.xanthocarpumsignificantly(P<0.05-P<0.001) and dose-dependently prevented drug induced increase in serum levels of hepatic enzymes. Furthermore,S. xanthocarpumsignificantly(up toP<0.001) reduced the LPO in the liver tissue and restored activities of defence antioxidant enzymes GSH, SOD and CAT towards normal levels. Histopathology of the liver tissue showed that S. xanthocarpumattenuated the hepatocellular necrosis and led to reduction in inflammatory cells infiltration.Conclusions:The results of this study strongly indicate the protective effect of S. xanthocarpumagainst liver injury which may be attributed to its hepatoprotective activity, and thereby scientifically support its traditional use.

Psychotropic drugs and liver disease:A critical review of pharmacokinetics and liver toxicity

The liver is the organ by which the majority of sub-stances are metabolized, including psychotropic drugs. There are several pharmacokinetic changes in end-stage liver disease that can interfere with the metabolization of psychotropic drugs. This fact is particularly true in drugs with extensive first--pass metabolism, highly protein bound drugs and drugs depending on phase I hepatic metabolic reactions. Psychopharmacological agents are also associated with a risk of hepatotoxicity. The evidence is insufficient for definite conclusions regarding the prevalence and severity of psychiatric drug-induced liver injury. High-risk psychotropics are not advised when there is pre-existing liver disease, and after starting a psychotropic agent in a patient with hepatic impairment, frequent liver function/lesion monitoring is advised. The authors carefully review the pharmacokinetic disturbances induced by end-stage liver disease and the potential of psychopharmacological agents for liver toxicity.

Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients

AIM:To evaluate the treatment options for nephrotoxicity due to cisplatin combination chemotherapy.METHODS:We retrospectively reviewed patients who had received cisplatin combination chemotherapy for gastric cancer between January 2002 and December 2008.We investigated patients who had shown acute renal failure(ARF),and examined their clinical characteristics,laboratory data,use of preventive measures,treatment cycles,the amount of cisplatin administered,recovery period,subsequent treatments,and renal status between the recovered and unrecovered groups.RESULTS:Forty-one of the 552 patients had serum creatinine(SCR)levels greater than 1.5 mg/dL.We found that pre-ARF SCR,ARF SCR,and ARF glomerular filtration rates were significantly associated with renal status postARF between the two groups(P=0.008,0.026,0.026,respectively).On the receiver operating characteristic curve of these values,a 1.75 mg/dL ARF SCR value had 87.5%sensitivity and 84.8%specificity(P=0.011).CONCLUSION:Cessation or reduction of chemotherapy should be considered for patients who have an elevation of SCR levels during cisplatin combination chemotherapy.

Toxic epidermal necrolysis related to AP(pemetrexed plus cisplatin)and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer

Toxic epidermal necrolysis(TEN) is a rare acute life-threatening mucocutaneous disorder that is mostly drug-related(80%-95%). It is clinically characterized as a widespread sloughing of the skin and mucosa. AP regimen(pemetrexed plus cisplatin) has been the preferred first-line chemotherapy for metastatic non-squamous non-small cell lung cancer(NSCLC). Gefitinib, a small-molecule epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI), has already been recommended as a first-line treatment in EGFR-mutant metastatic NSCLC. We report rare presentation of TEN involving adverse effects of AP and gefitinib combination treatment in a 42-year-old woman diagnosed with metastatic NSCLC harboring an EGFR mutation. On the 21 st day after administration of the first cycle of AP regimen and the 8th day after the initiation of gefitinib treatment, she developed an acne-like rash, oral ulcer, and conjunctivitis, which later became blisters and ultimately denuded. The characteristic clinical courses were decisive for the diagnosis of TEN. Treatment with systemic steroids and immunoglobulin as well as supportive treatment led to an improvement of her general condition and a remarkable recovery.

Body Composition as A Determinant of Pharmacokinetics and Toxicity of Anticancer Drugs

Chemotherapy-induced toxicity,resulting from inter-individual variability in pharmacokinetics is emerging as a highly active area of investigation.Body composition analysis,primarily concerning the amount of fat mass(FM)and lean body mass(LBM),has provided a proof-concept that the inter-individual variability in pharmacokinetics and toxicity profiles may be partially explained by the discrepancies of FM and LBM in patients.Recent research suggests a close relationship among body composition,pharmacokinetics and toxicity of anticancer drugs.Because LBM and FM,significantly influence the exposure to drugs,they are considered as the promising predictors of chemotherapy-induced toxicity and a potential basis for optimizing the dosing of oncology drugs and the outcomes.Our review summarizes the recent studies rendering the aforementioned correlations to highlight that a critical evaluation of body composition has initiated a new era for dose standardization.

Antiretroviral Therpay Induced Liver Toxicity among Immunecompromised HIV Patients at Chu Brazzaville

Introduction: Human immunodeficiency virus (HIV) infection is a public health problem of concern. Anti-retroviral therapy (ART) is associated with multiple side effects. This study aimed at identifying the different hepatic manifestations of antiretroviral therapy and the responsible molecules. Patients and Methods: This was an eight months period prospective descriptive study, from January 1st to August 31st, 2015, conducted in the Department of Gastroenterology and Internal Medicine at the Brazzaville University Teaching Hospital. Study participants were treatment-na?ve HIV patients who were initiated on ART treatment during the study period. Patients with liver disease, liver cytolysis prior to initiation of therapy, and those with alternative therapy that may cause hepatotoxicity were excluded. The sample size was 110 patients. Results: The age was ranging from 25 to 70 years with a mean age of 47.5 ± 7.5 years. During the six months of follow-up, the alarming hepatic signs were observed in 26.36% of cases (n = 29) in the 3rd month of treatment. There was no observed alarming sign in the 6th month of follow-up. The cytolytic pattern was observed in 54.55% of cases (n = 60) in the 3rd month. The cholestatic pattern was observed in 6.36% of cases (n = 7) in the 3rd month. Triple therapy combination of Zidovudine, Lamivudine and Nevirapine (AZT + 3TC + NVP) was the most used in 57.27% (n = 63) with a statistically significant p value to the occurrence of cytolytic pattern (p Conclusion: Drug induced liver toxicity occurs in a significant number of patients starting ART. The prevalence of hepatic events was high at the third month of treatment and the triple therapy of Zidovudine, Lamivudine and Nevirapine (AZT + 3TC + NVP) was the most incriminated.

Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity

Amphotericin B(AmB)is an amphiphilic drug commonly formulated in liposomes and administered intravenously to treat systemic fungal infections.Recent studies on the liposomal drug product have shed light on the AmB aggregation status in the bilayer,which heat treatment(curing)modifies.Although toxicity was found related to aggregation status-loose aggregates significantly more toxic than tight aggregates-the precise mechanism linking aggregation and toxicitywas notwell understood.This study directlymeasured drug release rate fromvarious AmB liposomal preparations made with modified curing protocols to evaluate correlations among drug aggregation state,drug release,and in vitro toxicity.UV–Vis spectroscopy of these products detected unique curing-induced changes in the UV spectral features:a∼25nm blue-shift of the main absorption peak(λ_(max))in aqueous buffer and a decrease in the OD_(346)/OD_(322) ratio upon thermal curing,reflecting tighter aggregation.In vitro release testing(IVRT)data showed,by applying and fitting first-order release kinetic models for one or two pools,that curing impacts two significant changes:a 3–5-fold drop in the overall drug release rate and a ten-fold decrease in the ratio between the loosely aggregated and the tightly aggregated,more thermodynamically stable drug pool.The kinetic data thus corroborated the trend independently deduced from the UV–Vis spectral data.The in vitro toxicity assay indicated a decreased toxicity with curing,as shown by the significantly increased concentration,causing half-maximal potassium release(TC50).The data suggest that the release of AmB requires dissociation of the tight complexes within the bilayer and that the reduced toxicity relates to this slower rate of dissociation.This study demonstrates the relationship between AmB aggregation status within the lipid bilayer and drug release(directly measured rate constants),providing a mechanistic link between aggregation status and in vitro toxicity in the liposomal formulations.

Toxic and drug—induced liver disease

930547 A study on hepatoxicity of thioglycolicacid through percutaneous administration.ZHANG Li(张黎),et al.Faculty Public Heal-ty,Harbin Med Univ,Harbin 150001.Chin J In-dustr Hyg & Occupat Dis 1993;11(2):69—72.Thioglycolic acid(TGA)in dosage of 30,100,300mg/kg was administered to rats by singledermal application in acute experiment.And thedosages were 5,50 and 150 mg/kg once a week insubchronic experiment whish lasted for 10weeks.The results showed disturbances of

Effects of chronic therapy with non-steroideal antinflammatory drugs on gastric permeability of sucrose: A study on 71 patients with rheumatoid arthritis

AIM: To evaluate the gastric permeability after both acute and chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) and to assess the clinical usefulness of sucrose test in detecting and following NSAIDs- induced gastric damage mainly in asymptomatic patients and the efficacy of a single pantoprazole dose in chronic users. METHODS: Seventy-one consecutive patients on chronic therapy with NSAIDs were enrolled in the study and divided into groups A and B (group A receiving 40 mg pantoprazole daily, group B only receiving NSAIDs). Sucrose test was performed at baseline and after 2, 4 and 12 wk, respectively. The symptoms in the upper gastrointestinal tract were recorded. RESULTS: The patients treated with pantoprazole had sucrose excretion under the limit during the entire follow-up period. The patients without gastroprotection had sucrose excretion above the limit after 2 wk, with an increasing trend in the following weeks (P = 0.000). A number of patients in this group revealed a significantly altered gastric permeability although they were asymptomatic during the follow-up period. CONCLUSION: Sucrose test can be proposed as a valid tool for the clinical evaluation of NSAIDs- induced gastric damage in both acute and chronic therapy. This tecnique helps to identify patients with clinically silent gastric damages. Pantoprazole (40 mg daily) is effective and well tolerated in chronic NSAID users.

Novel patterns for drug synergistic mechanism research

Drug combination based on synergistic effect is commonly used in clinical practice,especially in the application of traditional medicine.Exploring the combination mechanism could help to better utilize this synergistic advantage.However,current research focuses more on the efficacy enhancing of drugs,while ignoring the toxicity reducing effects.Here,we established two drug synergy patterns based on the different situations of drugs and targets,in order to better illuminate the synergistic mechanism of drugs.

Direct and Residual Microbicidal Efficacy of Various Antiseptics against Multi-Drug Resistant Bacteria

Background: Infections in ICU’s patients are known to often originate from the colonization of wounds by the patient’s endogenous microbiota, and to eventually lead to secondary sepsis. Aim: to compare in vitro the direct and residual effects after different exposure times of 4% chlorhexidine, and of 0.1% and 0.04% polyhexanide (in gel and solution forms), on ATCC-microorganisms, and too, on bacterial strains obtained from ICU patients. Methods: We used wild multi-drug resistant strains recently obtained from the wounds of patients hospitalized at ICU and reference strains from the American Type Culture Collection (ATCC). Chlorhexidine 4% was studied as a reference solution. The direct and residual effects of the 0.1% and 0.04% polyhexanide, in gel and solution forms, were analyzed using cotton germ carriers. To evaluate the direct effect, we exposed the strains to the antiseptic. To assess the residual effect, the germ-carriers were impregnated with antiseptic and were allowed to dry before we contaminated them. We inoculated the germ carriers in a culture medium with an inhibitor of antiseptic effect to count the number of surviving microorganisms. Findings: 0.1% Polyhexanide solution proved a direct and residual efficacy after 24 hours equivalent to 4% chlorhexidine. Is very important to highlight that this great efficacy did not change according to whether they were ATCC or multidrug-resistant strains. Conclusions: 0.1% polyhexanide demonstrated a great direct and residual efficacy (like 4% chlorhexidine), against multi-drug resistant strains isolated from ICU’s patients. Moreover, due to its few cytotoxicity against keratinocytes and fibroblasts can be an optimal antiseptic for burns, wounds or ulcers.

抗肿瘤分子靶向药物致化疗相关性腹泻的研究进展

化疗相关性腹泻(CRD)可导致治疗效果和患者依从性降低,影响肿瘤患者的长期治疗结局,甚至危及生命。除传统化疗药物外,许多分子靶向药物也可导致CRD,包括小分子表皮生长因子受体(EGFR)抑制剂、抗EGFR单克隆抗体、磷酸肌醇3-激酶抑制剂、血管内皮细胞生长因子受体小分子抑制剂、BCR-ABL1和KIT抑制剂、人表皮生长因子受体2靶点抑制剂、周期蛋白依赖性激酶抑制剂、抗体-药物偶联物等多种分子靶向药物。其发生机制可能与分子靶向治疗药物引起肠黏膜损伤或肠炎等有关,临床表现为大便频率增加和/或松散不成形,患者常伴有产气过多和/或肠绞痛。不同药物引起的CRD发生率不同,临床应重视病史采集和鉴别诊断,积极干预并进行动态评估,加强患者教育,以及时发现和预防肠毒性的发生。

磺胺类药物水环境行为及水生生物毒性研究进展

磺胺类药物(SAs)在水环境中普遍存在,大部分SAs以母体分子或代谢产物形式排放到环境中,地表水、地下水、海水甚至饮用水中都能检测到低浓度的SAs。因SAs排放量大、环境假性持久性强等特点,其对水生态环境和人类健康构成潜在风险。针对SAs在水环境中的归趋问题,总结了SAs在水环境中吸附、迁移、转化、降解、生物富集等典型行为规律,进一步分析SAs对水生植物、水生动物及水生微生物产生的毒性效应。结果表明:SAs在水环境中行为的研究多集中在环境介质表面的吸附特性与规律,而对SAs依赖水动力条件的迁移转化和生物富集规律研究较少;SAs在环境介质表面的吸附主要以阳离子交换和分子结合的形式发生,吸附质表面的电荷密度是决定吸附量的重要因素;SAs在水环境中广泛存在,虽然浓度水平较低,但对水生生物造成的负面影响会产生潜在的生态风险,主要表现为干预水生植物的生长发育过程,造成水生动物的特征性畸形,干扰水中微生物的群落结构与功能,最终会对整个水环境及其循环造成宏观的影响。未来应加强SAs在水环境中衰减过程的浓度和贡献率研究以及对水生生物毒性标准化测试,以期深入研究SAs生态毒理学、解决SAs污染问题。

两性霉素B脂质体治疗侵袭性真菌感染病人发生急性肾损伤危险因素分析

目的研究两性霉素B脂质体(L-AMB)治疗侵袭性真菌感染病人发生急性肾损伤(AKI)的危险因素。方法回顾性分析南京医科大学附属淮安第一医院2018年1月至2021年12月61例两性霉素B脂质体治疗侵袭性真菌感染病人的临床资料,根据是否发生两性霉素B脂质体相关AKI分为AKI组23例(37.7%),非AKI组38例(62.3%)。采用单因素分析法比较两组临床资料,logistic回归分析两性霉素B脂质体(L-AMB)治疗侵袭性真菌感染病人发生AKI的危险因素,应用受试者操作特征曲线(ROC曲线)评价L-AMB使用累积剂量及治疗前血清钾水平在诊断AKI方面的能力。结果有23例病人在使用L-AMB治疗过程中发生AKI,AKI发生率为37.7%。L-AMB疗程、累积剂量、日剂量,L-AMB治疗前血钾水平在AKI及非AKI两组病人比较中均差异有统计学意义(均P<0.05);累积剂量是发生L-AMB相关AKI的独立危险因素[OR=1.46,95%CI:(1.08,1.98),P=0.014];在L-AMB治疗前低血钾水平是发生L-AMB相关AKI的另一个独立危险因素[OR=0.05,95%CI:(0.01,0.43),P=0.007]。累积剂量和治疗前血钾水平曲线下面积(AUC)及其95%CI分别为0.88(0.79,0.98)、0.88(0.79,0.96),灵敏度分别为86.9%、81.5%,特异度分别为89.4%、86.9%。结论L-AMB累积剂量及治疗前低血钾水平均是L-AMB相关AKI的独立危险因素,两者在L-AMB相关AKI的诊断中均有一定的预测价值,而且累积剂量的诊断价值大于治疗前低血钾水平。

基于FAERS数据库的周期蛋白依赖性激酶4/6抑制剂血液毒性真实世界研究

目的 基于美国美国食品药品管理局(FDA)的不良事件报告系统(FAERS)分析3种周期蛋白依赖性激酶4/6(CDK4/6)抑制剂上市后的不良事件(AEs)信号,为临床用药安全提供参考。方法 提取FAERS数据库2015年第一季度至2022年第一季度共29个季度AEs,利用报告比值比法(ROR)和比例报告比值法(PRR)对CDK4/6抑制剂AEs进行数据挖掘。结果 CDK4/6抑制剂相关性血液毒性报告共有7 872份,各抑制剂血液毒性AEs占总AEs比例依次为哌柏西利(80.31%)>瑞博西利(15.36%)>阿贝西利(4.33%)。血液毒性常见中性粒细胞减少和贫血。哌柏西利(2 982/6 322,47.17%)和瑞博西利(613/1 209,50.70%)致中性粒细胞减少的报告占比较阿贝西利(117/341,34.31%)更高,血液毒性主要发生在药物开始使用后60 d内(1 630,61.86%),哌柏西利中位时间最长,且用药90 d后仍有32.9%的患者存在血液毒性,不同CDK4/6抑制剂血液毒性临床表现及发生强度存在差异。结论 哌柏西利、阿贝西利、瑞博西利均会导致明显的血液毒性,其中阿贝西利致血液毒性报告最少,但要警惕阿贝西利致贫血后导致死亡的风险。用药后的2个月内密切监测全血细胞计数,关注中性粒细胞、血红蛋白等水平,警惕CDK4/6抑制剂相关血液AEs的发生。

血管内皮生长因子及其受体抑制剂相关性高血压病理生理机制及临床诊疗的研究进展

肿瘤治疗相关心血管毒性(CTR-CVT)逐渐成为影响肿瘤幸存者预后的关键因素。以血管内皮生长因子(VEGF)为靶点研发的VEGF及其受体抑制剂(VEGFIs)作为新型抗肿瘤药物现已广泛应用于临床,可延长肿瘤患者的生存周期,改善患者预后,但VEGFIs诱导的高血压作为其最常见的CTR-CVT,可能会限制和影响其应用并引起严重心血管疾病(CVD)。对应用VEGFIs治疗的肿瘤患者应密切监测血压,早期评估,优化管理,使患者获得最佳的抗肿瘤疗效和最低的CTRCVT风险。现就VEGFIs相关性高血压的临床表现、发病机制、诊断和治疗策略进行综述,旨在为临床医生更好地管理和应对VEGFIs相关性高血压提供参考。

《医学衷中参西录》药物炮制撷英

张锡纯《医学衷中参西录》中有关药物炮制的内容非常丰富,在药物的净制方面,主要有麻黄去节、桂枝去皮、蜈蚣去头、竹茹的入药部位等;在药物的切制方面,主要有茯苓切片、用隔纸焙代替植物叶片使乳香、没药去油、五味子捣碎、石类药物轧细等;在矿物药炮制方面,主要有石膏、代赭石、赤石脂均宜用生品不需煅制,朱砂人工合成者不宜入药,并列举了玄明粉与黑锡丹的制作方法;动物药的炮制方面,龙骨、牡蛎、石决明、水蛭、全蝎均主张用生品,并列举了血余炭的制作方法;毒性药物的炮制方面,主要有鸦胆子不可使皮破并宜装入龙眼肉中吞服,市售半夏要漂去矾味并阐述了制作半夏的方法,拟定了马钱子新的减毒增效炮制方法;药物炒炭方面,除血余炭外,鲜用炒炭药物;药物发酵方面,认为麦芽虽为脾胃之药,而实善舒肝气;酒曲调气破癥的作用较神曲强,但是神曲性更平和,更适于健胃消食。

基于NRS2002 TEN和SJS患者的营养风险筛查

目的基于欧洲营养风险筛查工具(NRS2002)对中毒性表皮坏死松解症(TEN)和Stevens-Johnson综合征(SJS)患者进行营养风险筛查,研究TEN和SJS患者营养风险的发生率,探讨此类患者发生营养风险的危险因素。方法回顾性调查2011年1月至2021年3月在本院住院的临床资料完整的TEN和SJS患者215例,按受累皮肤的体表面积(BSA)予以区分TEN、SJS、SJS/TEN重叠综合征。同时基于NRS2002进行营养风险筛查评分,探讨TEN和SJS患者存在营养风险的危险因素。结果TEN和SJS患者入院时营养风险的发生率为64.19%(138/215)。其中,年龄(χ^(2)=7.198,P<0.01)、SCORTEN(χ^(2)=18.843,P<0.01)、致敏药物(χ^(2)=13.169,P<0.01)、皮损面积(χ^(2)=119.245,P<0.01)、黏膜受累部位(χ^(2)=8.241,P<0.01)对于TEN和SJS患者发生营养风险有统计学意义。多因素Logistic回归分析提示,年龄(OR=0.604,95%CI:0.472~0.973)、10%≤BSA≤30%(OR=4.638,95%CI:1.062-13.903)、BSA>30%(OR=6.128,95%CI:1.674~12.068)、黏膜受累部位为口腔黏膜(OR=5.978,95%CI:1.728~16.368)、血液净化治疗(OR=6.008,95%CI:1.316~22.175)是造成TEN和SJS患者营养风险的独立危险因素。结论大约2/3的TEN和SJS患者入院时即存在营养风险。而年龄、10%≤BSA≤30%、BSA>30%、黏膜受累部位为口腔黏膜、血液净化治疗则是造成TEN和SJS患者营养风险的独立危险因素。

抗结核药物所致QTc间期延长临床监测和管理专家共识

贝达喹啉、德拉马尼、氯法齐明及氟喹诺酮类药物(如左氧氟沙星、莫西沙星)对于提高耐多药和广泛耐药结核病的治疗成功率至关重要。然而,这些药物可能导致心电图的QTc间期延长,若不及时发现和处理,严重者可危及患者生命。因此,临床医师需要采取积极措施进行预防、监测和妥善处理。本共识旨在解决抗结核药物引发的QTc间期延长的临床监测和管理问题。依托公开发表的研究数据,以及参与专家的应用经验,经过深入的讨论,形成了关于抗结核药物导致的QTc间期延长的临床监测和管理的专业建议。希望本共识能够指导医生及时和规范地预防、发现、处理抗结核治疗过程中可能出现的QTc间期延长的不良反应。